Scholars Central

Conference abstractPublished 2 Nov 2015

Assessment of CCAAT/enhancer binding protein α gene methylation in acute myeloid leukemia patients in Egypt: relation to response to induction therapy

Authors: Nevene Ramsis

Canal University Medical School, Egypt

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Global gene promoter studies, as well as gene-specific approaches, have revealed that aberrant promoter methylation is a common event in AML. One such gene, CCAAT/enhancer binding protein α (C/EBP α), is a key transcription factor involved in the regulation of cell proliferation and differentiation in a variety of cell types, particularly in the hematopoietic system. Because of the pharmacologic reversibility of epigenetic changes by drugs, such as the DNA-demethylating agent, epigenetic therapy seems prominently among novel leukemia treatment strategies. Purpose: The present work is a cohort study that aimed at assessing the frequency of promoter methylation of the CEBP α gene in 70 cytogenetically normal, newly diagnosed AML Egyptian patients. Furthermore, the relation between the methylation status of the CEBP α gene and the outcome of standard induction therapy on day 28 was evaluated. Patients and methods: purified genomic DNA samples from the 70 newly diagnosed AML patients were subjected to bisulfate modification before methylation-specific polymerase chain reaction was performed to assess the CEBP α gene methylation status. Clinical and laboratory assessment of patients after 28 days of induction of standard therapy was performed. Results and conclusion: fifty-four percent of AML samples showed CEBP α gene methylation at the promotor region. Positive methylation was seen associated with blast expression of T-cell markers and blast counts in peripheral and bone marrow samples; but did not privilege a particular FAB classification subtype or relate to age and gender. The positive CEBP α gene methylation status was seen acceptable to predict AML patients with resistant clone who did not respond to standard induction therapy and blast clearance at day 28 (95% CI: 0.466–0.985, p= 0.005). Assessment of CEBP α gene methylation in AML patients might lead to refined prognostic stratification and suggest differentially tailored treatment based on its methylation status.

Subjects

Haematology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectHaematology
  • BylineArticles whose byline prints “Nevene Ramsis”